Diabetes care's annual rulebook lands, and obesity medicine moves toward the centre of it

The American Diabetes Association released its 2026 Standards of Care on 8 December, published as a supplement to the January 2026 issue of Diabetes Care [s1]. The document is revised annually by the ADA's Professional Practice Committee, an interprofessional expert panel, and it functions less as news than as infrastructure: it is what clinicians, payers, and quality-measurement programmes point at when they need a citable default [s2].

This year's revisions are worth reading for a specific reason. Several of them concern how obesity is treated rather than whether it is treated — a shift in the kind of question a diabetes guideline is being asked to answer.

What changed

The ADA's own summary of notable updates includes [s1]:

• Continuous glucose monitoring from diagnosis. CGM is recommended at diabetes onset and throughout management, for anyone who could benefit — not reserved for patients who have already failed something else.
• Fewer prerequisites for pumps and automated insulin delivery. Certain treatment prerequisites that had to be met before initiating continuous subcutaneous insulin infusion or automated insulin delivery have been removed.
• Guidance on individualising obesity-medication dosing in people with diabetes.
• New guidance on obesity treatment in type 1 diabetes — a population historically left out of obesity-pharmacotherapy recommendations.
• Updated glucose-lowering recommendations in chronic kidney disease, including patients on dialysis.
• Expanded guidance on therapies with heart, kidney, and liver benefits beyond glucose control.
• Named eating patterns for type 2 diabetes prevention: Mediterranean-style and low-carbohydrate approaches, framed as evidence-based options.
• Monitoring of nutritional adequacy and physical activity during obesity treatment.
• Glycaemic management guidance for people undergoing cancer treatment and organ transplantation.
• Revised blood pressure targets — tighter for people at high cardiovascular risk, relaxed for most older adults.
• Expanded screening and monitoring for type 1 diabetes risk.

Rita Kalyani, MD, MHS, the ADA's chief scientific and medical officer, said the 2026 Standards represent "significant advancement in the delivery of evidence-based, person-centered care" [s1]. The committee is co-chaired by Mandeep Bajaj, MBBS, FRCP and Rozalina G. McCoy, MD, MS, and seven organisations endorsed specific sections, among them The Obesity Society and the National Kidney Foundation [s1].

Why the dosing and nutrition items matter more than they look

Two of these changes are small in wording and large in practice.

The first is dose individualisation for obesity medications [s1]. Trials of incretin-based drugs are run to a target dose, and the clinical literature is largely a literature about maximum tolerated doses. Real practice looks different — patients plateau, tolerate poorly, run into supply or cost interruptions, or reach a weight they want to hold. A guideline that acknowledges dosing as a decision rather than a protocol is describing what already happens in clinics and giving it a citation.

The second is monitoring nutritional adequacy and physical activity during obesity treatment [s1]. Rapid weight loss on these drugs reduces food intake sharply, and with it protein and micronutrient intake. The guideline is not making a claim about lean-mass loss; it is instructing clinicians to watch the inputs. That is a modest, defensible position on a question the field has argued about loudly and settled incompletely.

What a guideline is and is not

The Standards of Care are consensus recommendations graded on an evidence system, not new data. Nothing in a December guideline release has been tested by the guideline. Its authority comes from the committee's reading of trials that were already published, and its recommendations inherit every limitation of those trials — including which populations were studied and which were not.

That caveat has teeth for the type 1 diabetes item. Obesity pharmacotherapy in type 1 diabetes has a far thinner evidence base than in type 2, because trials of these drugs have generally excluded people with type 1. A recommendation extending into that space is doing more extrapolating than one covering type 2.

The nutrition recommendations carry a related caveat. Naming Mediterranean-style and low-carbohydrate eating patterns as evidence-based options for type 2 diabetes prevention [s1] is a statement about patterns with supporting trial and cohort evidence — not a ranking, and not a claim that either outperforms the other for any particular person.

What to watch

Whether payers follow the CGM-at-diagnosis recommendation, which is where guideline language usually meets its real test. Whether the removal of prerequisites for automated insulin delivery changes who actually gets one. And whether the dose-individualisation guidance shows up in prescribing data over 2026, or stays a sentence in a supplement.

This article describes a clinical guideline. It is not medical advice, and decisions about diabetes or obesity treatment belong with a clinician who knows the individual case.

Sources

1. The American Diabetes Association Releases "Standards of Care in Diabetes—2026" — American Diabetes Association, 8 December 2025
2. 8. Obesity and Weight Management for the Prevention and Treatment of Diabetes: Standards of Care in Diabetes—2026 — Diabetes Care, 8 December 2025